Previous 10 | Next 10 |
Topline Data from Five Pivotal Phase 3 Trials in 2023 Total Company Revenue $140.7 Million in 2022 Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results...
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of t...
FibroGen ( NASDAQ: FGEN ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is -$0.94 and the consensus Revenue Estimate is $23.95M (+44.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revi...
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment ...
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time. The ...
FibroGen ( NASDAQ: FGEN ) added ~3% pre-market Tuesday after William Blair upgraded the clinical-stage biotech citing the potential of its lung disease candidate pamrevlumab following similar moves by at least two other Wall Street firms this month. The company has exclusive right...
Summary Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate Sparsentan. Indicated for kidney disease IgAN and FSGS, the accelerated approval would be granted based on the drug's ability to reduce proteinuria. ...
Raymond James has upgraded FibroGen to outperform from market perform as it sees bullish prospects for phase 3 idiopathic pulmonary fibrosis ( IPF ) candidate pamrevlumab. The firm has a $35 price target (69% upside based on Wednesday's close). Shares are up 8% in Thursday mo...
Bank of America on Thursday upgraded FibroGen ( NASDAQ: FGEN ) to Buy from Neutral on favorable risk-reward ahead of the release of key topline data for pamrevlumab in treatment of idiopathic pulmonary fibrosis. FibroGen ( FGEN ), which gained ~48% in the last s...
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time. A ...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...